目的 探討地塞米松聯(lián)合卡前列素氨丁三醇治療高危妊娠產(chǎn)婦產(chǎn)后出血的臨床療效及其安全性評價。方法 選取2014年6月-2016年6月在岐山縣醫(yī)院分娩的高危妊娠產(chǎn)婦80例，將其隨機分為兩組，A組和B組，每組40例，A組產(chǎn)婦接受卡前列素氨丁三醇止血治療，B組產(chǎn)婦接受地塞米松聯(lián)合卡前列素氨丁三醇治療，比較兩組產(chǎn)婦產(chǎn)后出血治療的臨床療效和出血情況，比較分析兩組產(chǎn)婦產(chǎn)后出血治療期間不良反應的發(fā)生情況。結(jié)果 經(jīng)治療，兩組患者產(chǎn)后出血的總有效率差異不顯著。兩組產(chǎn)婦在分娩過程中分別給藥0.5 h后，收縮壓（SBP）、舒張壓（DBP）及心率（HR）較給藥前顯著升高（P<0.05），但是各指標兩組產(chǎn)婦之間比較無顯著差異。分娩后2 h內(nèi)和2~24 h，B組出血量顯著較A組少，差異有統(tǒng)計學意義（P<0.05）；兩組產(chǎn)婦產(chǎn)后休克指數(shù)（Shock index，SI）差異不顯著。B組惡心嘔吐的發(fā)生率顯著低于A組，差異有統(tǒng)計學意義（P<0.05），且B組不良反應的總發(fā)生例數(shù)顯著少于A組，差異有統(tǒng)計學意義（P<0.05）。結(jié)論 地塞米松聯(lián)合卡前列素氨丁三醇治療高危妊娠產(chǎn)婦產(chǎn)后出血的臨床療效顯著，可顯著控制產(chǎn)婦產(chǎn)后出血量和并降低治療期間不良反應的發(fā)生率，安全性較好，值得臨床推廣應用。

Objective To explore the curative effect and safety of romethamine combined with dexamethasone on the postpartum hemorrhage for patients with high risk pregnancy. Methods 80 patients with high risk pregnancy were enrolled in our hospital from June 2014 to June 2016, of which patients divided into two group randomly, Group A (n=40) accepted romethamine for hemostasis treatment, and Group B (n=40) adopted romethamine combined with dexamethasone treatment. The clinical effect and hemorrhage of patients with postpartum hemorrhage were compared, and the adverse reactions were recorded and analyzed in the period of treatment. Results After treatment, the difference of total effective rate for postpartum hemorrhage from two groups was no significance. After given medicines 0.5 h respectively in delivery process, the SBP, DBP and HR of all parturient women were rising compared with before medicine administration remarkably (P<0.05), but the difference of those between two groups was no significance. Within 24 h after delivery, the hemorrhage of Group B was lower significantly than those patients in Group A (P<0.05). The difference of shock index (SI) from Group A and Group B was no significance. The incidence of nausea and vomiting in Group B was lower than those Group A significantly (P<0.05), and the case of total adverse reactions in group B was fewer significantly than those Group A (P<0.05). Conclusions The romethamine combined with dexamethasone for the postpartum hemorrhage in patients with high risk pregnancy deserved popularization in clinic, of which not only possessed remarkably clinical effect and well safety, but also controlled the postpartum hemorrhage effectively and decreased the incidence of the adverse reactions in the period of treatment.